- Conditions
- Prostate Cancer
- Interventions
- Luteinizing hormone-releasing hormone (LHRH), Docetaxel, Conformal Radiation Therapy (RT)
- Drug · Other
- Lead sponsor
- Proton Collaborative Group
- Network
- Eligibility
- 18 Years to 75 Years · Male only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 3
- States / cities
- Warrenville, Illinois • Oklahoma City, Oklahoma • Hampton, Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–46
of 22
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer, Castration-resistant Prostate Cancer, Biochemically Recurrent Prostate Carcinoma
- Interventions
- Abiraterone, Apalutamide, Biospecimen Collection, Bone Scan, Computed Tomography, Darolutamide, Degarelix, Enzalutamide, Goserelin, Histrelin, Leuprolide, Magnetic Resonance Imaging, Patient Observation, Positron Emission Tomography, Prednisone, Questionnaire Administration, Relugolix, Stereotactic Body Radiation Therapy, Triptorelin, Radiation Therapy, Image-Guided Therapy
- Drug · Procedure · Other + 1 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 532 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Prostate Cancer
- Interventions
- DFMO, testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Enzalutamide
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Prostatic Neoplasms
- Interventions
- Radiotherapy, LHRHa, Apalutamide
- Radiation · Drug
- Lead sponsor
- Janssen Pharmaceutica N.V., Belgium
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 691 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2031
- U.S. locations
- 13
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 10 more
- Conditions
- Prostate Cancer
- Interventions
- ARN-509, LHRH Agonist
- Drug
- Lead sponsor
- Aragon Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • San Francisco, California • Chicago, Illinois + 2 more
- Conditions
- Prostate Cancer
- Interventions
- bicalutamide, docetaxel, flutamide, LHRH agonist, 3-dimensional conformal radiation therapy, radiation therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2018
- U.S. locations
- 69
- States / cities
- Phoenix, Arizona • Auburn, California • Cameron Park, California + 60 more
- Conditions
- Breast Cancer
- Interventions
- GDC-9545, Palbociclib, LHRH Agonist
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Boston, Massachusetts • New York, New York + 1 more
- Conditions
- Prostate Cancer
- Interventions
- bicalutamide, flutamide, LHRH agonist (antagonist) therapy, Dose-Escalated Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,538 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2025
- U.S. locations
- 499
- States / cities
- Birmingham, Alabama • Fairbanks, Alaska • Peoria, Arizona + 353 more
- Conditions
- Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Interventions
- Apalutamide, Bicalutamide, Biospecimen Collection, Bone Scan, Buserelin, Computed Tomography, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Magnetic Resonance Elastography, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Relugolix, Triptorelin
- Drug · Procedure · Other + 1 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 2,753 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2038
- U.S. locations
- 594
- States / cities
- Fairbanks, Alaska • Gilbert, Arizona • Peoria, Arizona + 438 more
- Conditions
- Early Breast Cancer
- Interventions
- Giredestrant, Physician's Choice of Endocrine Therapy, LHRH Agonist
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2033
- U.S. locations
- 72
- States / cities
- Daphne, Alabama • Bakersfield, California • Fullerton, California + 66 more
- Conditions
- Central Precocious Puberty
- Interventions
- Debio 4326
- Drug
- Lead sponsor
- Debiopharm International SA
- Industry
- Eligibility
- 5 Years to 8 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 3
- States / cities
- San Diego, California • San Francisco, California • Columbia, South Carolina
- Conditions
- Prostate Cancer
- Interventions
- Radiation Therapy, Enzalutamide, Bicalutamide, GnRH analog
- Radiation · Drug
- Lead sponsor
- RTOG Foundation, Inc.
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 106
- States / cities
- Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 89 more
- Conditions
- Prostate Cancer
- Interventions
- Radiation, Androgen Suppression Therapy
- Radiation · Drug
- Lead sponsor
- Proton Collaborative Group
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Warrenville, Illinois • Oklahoma City, Oklahoma + 1 more
- Conditions
- Prostate Adenocarcinoma
- Interventions
- Behavioral Dietary Intervention, Counseling, Educational Intervention, Exercise Intervention, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate, Quality-of-Life Assessment, Triptorelin Pamoate
- Behavioral · Other · Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- Male only
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Prostate Cancer
- Interventions
- Bicalutamide, Leuprolide, Goserelin, Triptorelin, Docetaxel, Abiraterone, Apalutamide, Enzalutamide
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 21 Years to 85 Years · Male only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Triptorelin Pamoate, placebo
- Drug · Other
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 9 Years to 21 Years · Female only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2014
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Chicago, Illinois • Hackensack, New Jersey + 6 more
- Conditions
- Prostate Cancer
- Interventions
- Triptorelin pamoate, Leuprolide acetate
- Drug
- Lead sponsor
- Watson Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 16
- States / cities
- Homewood, Alabama • Daytona Beach, Florida • Orange City, Florida + 13 more
- Conditions
- Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
- Interventions
- Exemestane, Laboratory Biomarker Analysis, Oophorectomy, Quality-of-Life Assessment, Radiation Therapy, Tamoxifen, Triptorelin
- Drug · Other · Procedure + 1 more
- Lead sponsor
- ETOP IBCSG Partners Foundation
- Network
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 3,066 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2024
- U.S. locations
- 480
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 323 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Darolutamide
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
- Interventions
- exemestane, triptorelin pamoate, capecitabine, methotrexate, vinorelbine tartrate, paclitaxel, therapeutic conventional surgery, radiation therapy, laboratory biomarker analysis
- Drug · Procedure · Radiation + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Breast Cancer, Hormone Changes, Drug Toxicity
- Interventions
- triptorelin
- Drug
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- Up to 44 Years · Female only
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 9
- States / cities
- Oakland, California • Tampa, Florida • Augusta, Georgia + 5 more
- Conditions
- Prostate Cancer
- Interventions
- Trelstar, Lupron, Zoladex
- Drug
- Lead sponsor
- Pharmatech
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 11
- States / cities
- Tucson, Arizona • Hot Springs, Arkansas • Fresno, California + 7 more